Drug-interaction ML: representation and validation review framework

Evidence & verification

Source level

Peer-reviewed source
Grounded in a peer-reviewed publication. This describes the source; it does not mean the reported results have been independently reproduced.

Outcome verification

Not empirically evaluated here
A documented resource or intended workflow, not a demonstrated academic outcome. No empirical benefit is established by its inclusion.

Sources checked

2026-10-19 (UTC)

Source scope: Primary abstract and policy checked October 19; selected archived primary PDF excerpts retain their October 17 retrieval date. Documentation/reference inclusion does not establish an empirical research benefit. The journal-source label follows publication identity and available journal metadata/policy, not an audit of review conduct or scientific quality.

Source-checked does not mean independently reproduced. See the Method page for how these labels are assigned.

Sources (2)

Research applicability

Nonnumeric representation, validation and reproducibility dimensions for drug-interaction ML research.

Getting started

Read the linked primary sources and the stated adoption requirements. Reuse suggestions are editorial and untested; no setup recipe or trial was executed.

Maintenance

Sources last checked on 2026-10-19. Future availability, maintenance, provider terms and compatibility were not verified.

License

Article, about-page and footer licence statements differ; exact reuse terms remain unresolved.

Workflow & human oversight

No workflow level assigned. The review supplies nonnumeric reference dimensions for algorithm families, features, datasets, validation and metrics. AI in the prediction studies does not establish AI performing the review or one supervised AI research workflow. An archived PDF excerpt’s incompatible study-quality counts remain unresolved; comparative results are not accepted here.

Workflow level is not an evidence score; higher is not better evidence.

Approach

The abstract describes PRISMA-oriented searching, independent screening/extraction and adapted PROBAST appraisal, then compares algorithms, features, datasets, validation and metrics. Cold-start generalisation, interpretability, real-world evaluation and reproducibility are reference dimensions, not verified performance findings.

Limitations

Primary Indonesian abstract, selected journal policy and retained October 17 PDF excerpts only; not a fresh complete-PDF review, clinical data/model audit or reproduction of included studies. The abstract’s all-60-high-quality wording conflicts with a retained results figure of 63.3%; no pooled performance or quality-count conclusion is adopted. Inconsistent scope/licence boilerplate, drafting artefacts, unrelated footer links and differing policy reviewer counts limit provenance confidence; they do not prove compromise or misconduct. The journal-source label follows article identity/stated policy, not verified review conduct. No clinical impact, prescribing inference or drug-interaction advice is supplied.

Reproducibility

Source text was checked only within this scope: Primary abstract and policy checked October 19; selected archived primary PDF excerpts retain their October 17 retrieval date. No software, dataset, experiment or result was independently reproduced.

Adoption requirements

Untested suggestion: use only as a bounded checklist and verify full methods, study independence, leakage, external/cold-start validation and provenance before research reuse.

Comments

No comments yet.

Add a comment

Comments are held for moderation before appearing. Critical or corrective comments are welcome — especially evidence that an entry overstates what has been verified.